Vedanta Biosciences has published additional results from its Phase 2 CONSORTIUM study for VE303, a potential first-in-class ...
Vedanta Biosciences, a late clinical-stage company developing defined bacterial consortia as oral therapies for gastrointestinal diseases, today announced the publication of additional results from ...
PureTech Health (PRTC) noted that its founded entity, Vedanta Biosciences, a late clinical-stage company developing defined bacterial consortia ...
Biosciences' lead drug candidate, VE303, has been reported to demonstrate efficacy in preventing recurrent Clostridioides ...
11d
Topline data for the ongoing Phase 3 pivotal RESTORATiVE303 study are expected in 2026 ...
Neurocrine Biosciences, Inc. today announced that Andrew Ratz, Ph.D., has joined the company as Senior Vice President of Drug Development, Delivery and Device. In this role, Dr. Ratz will lead the ...
CAMBRIDGE, Mass., January 23, 2025--(BUSINESS WIRE)--Vedanta Biosciences, a late clinical-stage company developing defined bacterial consortia as oral therapies for gastrointestinal diseases ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vedanta Biosciences, a late clinical-stage company developing defined bacterial consortia as oral therapies for gastrointestinal diseases, today announced the ...
Vedanta Biosciences, a late clinical-stage company developing defined bacterial consortia as oral therapies for gastrointestinal diseases, today announced the publication of additional results ...
The Kumbh festival, rooted in ancient Indian mythology, symbolizes the quest for immortality and the philosophical insights of Vedanta. Understanding the deeper meanings behind its stories leads ...
Companies like Vedanta Biosciences and Finch Therapeutics are leading the way with novel drugs like CP101 for Clostridioides difficile illness and Seres Therapeutics' SER-287 for autistic spectrum ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback